DrugDashboards

Hydrocortisone sodium succinate

Hydrocortisone sodium succinate · HYDROCORTISONE SODIUM SUCCINATE 100 mg/2mL · Injection · Intramuscular; Intravenous · Zydus Lifesciences Limited

NDC 70771-1966-01 · 1 VIAL in 1 CARTON / 2 mL in 1 VIAL · ANDA · View full market →

The short version

Just 3 companies supply this market — thin enough that a single exit would be felt immediately. A shortage here was resolved within the past year — markets usually stay tight for a while after. Historically, drugs in this position went on to a new shortage within 90 days about 0.6% of the time — roughly 4× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.6%chance of a new FDA shortage posting for hydrocortisone sodium succinate (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 4× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA217191
TE code
AP
Approval date
May 7, 2026
Patents / exclusivity
None on file

Shortage history

  • Shortage ended Hydrocortisone Sodium Succinate, Injection, 100 mg/ Vial (NDC 69097-004-67)Mar 24, 2023 → Feb 24, 2026

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Hydrocortisone sodium succinate (Injection)

LabelerStrengthFirst seenLast seen
Cipla USA Inc.HYDROCORTISONE SODIUM SUCCINATE 100 mg/2mLJul 15, 2026Sep 2, 2026
Zydus Lifesciences LimitedHYDROCORTISONE SODIUM SUCCINATE 100 mg/2mLJul 15, 2026Sep 2, 2026
Zydus Pharmaceuticals USA Inc.HYDROCORTISONE SODIUM SUCCINATE 100 mg/2mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Hydrocortisone sodium succinate — NDC 70771-1966-01," retrieved September 3, 2026, https://drugdashboards.com/drug/70771196601.

Free to cite with attribution — see how the data is put together.